TABLE 6.
Risperidone (Median or Mean ± SD) | Clozapine (Median or Mean ± SD) | Aripiprazole (Median or Mean ± SD) | Health control group (Median) | ANOVA or Kruslal-Wallis | pa | pb | pc | pd | pe | pf | |
TNF-α (pg/ml) | 7.14 | 7.20 | 7.22 | 4.50 | 0.024 | 0.695 | 0.935 | 0.008** | 0.561 | 0.037 | 0.009 |
IL-33 (pg/ml) | 79.14 | 84.83 | 72.67 | 82.50 | 0.660 | 0.914 | 0.310 | 0.507 | 0.256 | 0.871 | 0.499 |
TGF-β (pg/ml) | 210.5 ± 113.5 | 275.1 ± 106.1 | 266.9 ± 117.7 | 303.6 ± 102.4 | 0.032 | 0.237 | 0.334 | 0.018* | 0.997 | 0.680 | 0.552 |
The Shapiro-Wilk normality test. One-factor ANOVA or Kruskal-Wallis test was used. For subsequent tests within ANOVA, post-processing with the Tukey test was applied. Mann-Whitney U test. Bonferroni correction (we will consider the results of subsequent tests to be statistically significant if the p value is less than 0.0083). In the part of descriptive statistical analysis, average values and standard deviation for data that follow the normal distribution and median values for data that do not follow the normal distribution are shown.
IL, Interleukin; TNF, Tumor Necrosis Factor; TGF, Transforming growth factor; pa: Risperidone vs. Clozapine group; pb: Risperidone vs. Aripiprazole group; pc: Risperidone vs. health control group; pd: Clozapine vs. Aripiprazole group; pe: Clozapine vs. health control group; pf: Aripiprazole vs. health control group.